CMG190303(Dapagliflozin/Rosuvastatin)

Phase 3Small molecule

CMG190303(Dapagliflozin/Rosuvastatin) is one of 24 small molecule programs targeting Type 2 Diabetes. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 DiabetesActive, not recruiting

Type 2 DiabetesPhase 3

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Jardiance

Boehringer Ingelheim

Preclinical

31 2

NOVOLIN R

Novo Nordisk

Preclinical

5 3

CMG190303(Dapagliflozin/Rosuvastatin)

CCMG Pharmaceutical Co. Ltd

Phase 3

1 4

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 5

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 6

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 7

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 8

Forxiga

AstraZeneca

Preclinical

3 9

Lovaza

AstraZeneca

Preclinical

1 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Type 2 Diabetes

NCT06772168

Clinical

Trials by Indication[1]

Type 2 Diabetes1 trial

Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia

Recruiting·CCMG Pharmaceutical Co. Ltd·Phase 3·NCT06772168·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CMG190303(Dapagliflozin/Rosuvastatin). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CMG190303(Dapagliflozin/Rosuvastatin) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CMG190303(Dapagliflozin/Rosuvastatin). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CMG Pharmaceutical Co. Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCMG Pharmaceutical Co. Ltd

CMG190303(Dapagliflozin/Rosuvastatin)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Type 2 Diabetes1 trial

References

Drug Info

Quick Facts

Related News